With the limitation of a small sample size (n = 12), PD-1 ICB administration after CD30 CAR T-cell therapy in CD30+ lymphoma patients (n = 9 cHL, n = 1 angioimmunoblastic T-cell lymphoma, n = 2 gray zone lymphoma) suggested improved efficacy (ORR 86% versus 100%; CR 27% versus 80%) (Table 3) [111]. Here, TNFRSF8 is linked to classic Hodgkin lymphoma.